At-Home Alzheimer's Treatment Poised for Accelerated Approval in China

STOCKHOLM, Sweden – February 09, 2026 – A groundbreaking shift in Alzheimer's disease management is on the horizon in China, as regulators have granted Priority Review status to a new, at-home formulation of the drug Leqembi (lecanemab). The decision by China's National Medical Products Administration (NMPA) signals a major step toward making the treatment more accessible for the millions of people grappling with the early stages of the neurodegenerative disease.

The application, submitted by pharmaceutical company Eisai, a partner of Leqembi's Swedish inventor BioArctic, is for a subcutaneous autoinjector (SC-AI). If approved, this would allow patients or their caregivers to administer the drug via a simple weekly injection at home, replacing the current regimen of intravenous (IV) infusions every two weeks in a hospital setting.

This regulatory fast-tracking could significantly shorten the review timeline, potentially bringing this more convenient option to the Chinese market sooner than expected. The move reflects a growing global trend toward patient-centric care and highlights China's commitment to addressing its escalating public health challenges.

A Paradigm Shift for Patients and Caregivers

For the estimated 17 million people in China living with mild cognitive impairment or mild dementia due to Alzheimer's disease, the current treatment protocol presents significant logistical hurdles. It involves regular travel to a medical facility, time spent in waiting rooms, and the process of the IV infusion itself, which is monitored by nursing staff. This places a substantial burden not only on patients but also on their families and caregivers, who often must take time off work to manage these frequent appointments.

The proposed subcutaneous autoinjector is designed to revolutionize this experience. The weekly dose of 500 mg would be delivered via two separate 250 mg injections, with each injection taking approximately 15 seconds. This transition from a bi-weekly, hours-long hospital visit to a quick, weekly administration in the comfort of one's own home represents a monumental improvement in quality of life.

Beyond patient convenience, the shift has profound implications for China's healthcare system. With a rapidly aging population—ADRD cases in the country tripled between 1990 and 2021—the demand on healthcare resources is immense. By moving treatment out of the clinic, the subcutaneous formulation could free up hospital capacity, reduce the need for nurse monitoring associated with infusions, and streamline the entire Alzheimer's care pathway. This is particularly critical in a country where the prevalence of mild cognitive impairment among adults over 60 is already estimated to be as high as 17%.

Navigating China's Evolving Healthcare Landscape

The NMPA's decision to grant Priority Review is a testament to China's evolving regulatory strategy. The procedure is designed to accelerate the approval of innovative medicines that demonstrate significant clinical value, shortening the standard 200-day review period to around 130 days. This initiative is part of a broader effort by Chinese authorities to foster pharmaceutical innovation and ensure its population gains faster access to cutting-edge therapies.

Equally significant is Leqembi's recent inclusion on China's 'Commercial Insurance Innovative Drug List' (CIIDL), which took effect in January 2026. This new reimbursement pathway is a crucial component of China's multi-tiered insurance system, designed to cover high-value, innovative drugs that may not yet be included on the primary National Reimbursement Drug List (NRDL). Inclusion on the NRDL often requires steep price negotiations, but the CIIDL provides an alternative route for patient access by encouraging commercial insurers to develop products that cover these advanced treatments.

For a drug like Leqembi, this dual benefit of an expedited regulatory review and a viable commercial reimbursement channel creates a powerful combination for market penetration. It allows Eisai and BioArctic to reach patients more quickly while establishing a framework for affordability outside the constraints of the state's basic medical insurance program.

A Strategic Move in a High-Stakes Market

The push for a subcutaneous version of Leqembi is a calculated strategic maneuver in the competitive Alzheimer's treatment market. Leqembi, which targets the amyloid-beta protofibrils believed to cause brain injury in Alzheimer's, was first launched in China's private market in June 2024. However, it faces competition from other amyloid-targeting therapies, including Eli Lilly's Kisunla (donanemab), which was approved in China in late 2024 and is also administered via IV infusion.

By introducing a more convenient at-home option, Eisai and BioArctic can create a powerful differentiator that appeals directly to patients and caregivers. This focus on ease of use could provide a significant competitive advantage and help secure a larger share of the vast and growing Chinese market. For BioArctic, the inventor of the antibody, success in China translates directly to financial returns through royalties and potential sales milestone payments from its long-standing partnership with Eisai, which handles global clinical development and commercialization.

This strategy is not limited to China. The partners are pursuing subcutaneous formulations across major global markets. A similar formulation for maintenance dosing is already approved in the United States, and applications have been submitted in Japan and are under Priority Review in the U.S. for use as a starting dose. This global push underscores a clear corporate vision: making a disease-modifying therapy for Alzheimer's not just effective, but also as manageable as possible for those who depend on it. As research continues into even earlier, preclinical stages of Alzheimer's, such as in the ongoing AHEAD 3-45 study, ensuring the treatment is sustainable for long-term use will become ever more critical.